Beta Bionics, Inc. (BBNX) PT Raised to $21 at Truist Securities

Truist Securities analyst Richard Newitter raised the price target on Beta Bionics, Inc. (NASDAQ: BBNX) to $21.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "2Q Rev/GM Beat & Raise on Above-CNS New Patient Starts and Outperformance in the PBP Channel; BBNX shares shld see strength---and could regain some recently lost ground--- following a solid 2Q rev/EPS beat driven by new patient start (NPS) upside & a +$6M FY25 rev gdce raise (> the $3.5M 2Q beat). Even w/ the NT headwind accompanying a higher pharmacy NPS outlook ($1M FY25 headwind, $9M cumulative '26-'28 tailwind) mgmt. still raised both rev & GM outlooks, which speaks to strong adoption trends. Meanwhile, an accel. pharmacy channel shift has even bigger +ve out-year est. implications increasing our confidence BBNX can sustain a premium rev growth profile (30-40%+ '24-'28E CAGR). Our PT increases to $21 PT (vs. $18) on increasing est.'s. Reit Buy."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Aurora Spine settles patent dispute, secures $600K insider loan
• Phillips 66, Marathon Merger Talks Collapsed - Semafor